BIGBEAR
PHARMACEUTICAL
Pralsetinib inhibits the abnormal activation of RET protein and blocks downstream signaling pathways.
AuthenticGuaranteeFast DeliveryPrivacy Pralsetinib was approved for marketing by the U.S. Food and Drug Administration (FDA) in September 2020, and subsequently approved in several countrie···【More】
Update: 06 Mar,2026Source: BigbearViews: 85
Pralsetinib is a potent, highly selective RET tyrosine kinase inhibitor developed by Blueprint Medicines, Inc. It is used to treat RET fusion-positive···【More】
Update: 06 Mar,2026Source: BigbearViews: 87
Pralsetinib is a potent, highly selective RET tyrosine kinase inhibitor developed by Blueprint Medicines, Inc. It is used to treat RET fusion-positive···【More】
Update: 06 Mar,2026Source: BigbearViews: 85
Pralsetinib is a receptor tyrosine kinase (RET) inhibitor. It was approved for marketing by the US FDA in 2020.Side effects requiring immediate medica···【More】
Update: 06 Mar,2026Source: BigbearViews: 86
On August 9, 2023, the U.S. Food and Drug Administration (FDA) granted regular approval to pravlatinib (Gavreto, Genentech) for the treatment of adult···【More】
Update: 06 Mar,2026Source: BigbearViews: 87
On September 4, 2020, Genentech, a Roche company, announced that the U.S. Food and Drug Administration (FDA) has approved pramintinib (Gavreto) for th···【More】
Update: 06 Mar,2026Source: BigbearViews: 85
Pralsetinib, developed by Blueprint Medicines, is an oral, highly selective, and potent RET inhibitor.Common Dosages for Pralsetinib1. Adult Non-Small···【More】
Update: 06 Mar,2026Source: BigbearViews: 91
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
